What Otsuka Pharmaceutical does

Otsuka Pharmaceutical Co., Ltd. is a Tokyo-headquartered Japanese pharmaceutical company founded in 1964 and operating as the principal healthcare subsidiary of publicly listed Otsuka Holdings Co., Ltd. (TYO: 4578; OTSKY on US OTC). The company runs a dual business model spanning a pharmaceutical business and a nutraceuticals/consumer health business. The pharmaceutical business develops and commercializes small-molecule drugs and biologics across CNS (centanafadine, TSND-201 via Transcend), oncology (Inaqovi for AML, OPB-171775 for GIST), cardiovascular/renal (VOYXACT for IgA nephropathy, NEXLETOL for hypercholesterolemia, Paradise Renal Denervation system), and rare diseases (repinatrabit/JNT-517 for phenylketonuria via Jnana Therapeutics). The nutraceuticals business markets functional beverages (Pocari Sweat, OS-1, Oronamin C), nutritional supplements (Calorie Mate, Nature Made, SOYJOY, /zeroz, EQUELLE), and cosmeceuticals (InnerSignal, UL-OS, sakuraé) primarily in Japan with selective international distribution. Distribution runs through medical representative (MR) detailing for prescription products and through mass retail, convenience stores, drugstores, and the Otsuka Plus One e-commerce platform for consumer products, supplemented by regional commercialization partners (GENESIS Pharma, Sky Labs, 4DMT) for international market access.

The company generates revenue through three principal streams: (1) prescription pharmaceutical product sales (originator drugs sold via hospital and retail pharmacies in Japan, the US, and Europe), (2) nutraceuticals and consumer health product sales (Pocari Sweat, Calorie Mate, Nature Made, etc., sold through retail and DTC channels), and (3) licensing, milestone, and royalty income from out-licensed pipeline assets and commercialization partnerships (e.g., $90M milestone to Esperion upon NEXLETOL Japan launch, $140M upfront from 4DMT, Biodexa licensing of OPB-171775 with mid-single-digit royalties). Pricing for Rx products is set through national health insurance systems in Japan, EU reimbursement negotiations, and US payer contracts; consumer products are priced at retail. Pricing model types reported include one-time license sales for product revenue and licensing/royalties for partnership income. Customer segments split between healthcare providers and patients (CNS, oncology, cardiovascular/renal, rare disease therapeutics) and general consumers (daily hydration, nutrition, women's health, skincare). Geographic footprint spans Japan, the United States, Europe, Korea, China, and other Asia-Pacific markets, with operations in 100+ countries for pharmaceutical and consumer health products.

The company's competitive position rests on a diversified therapeutic pipeline (>10 late-stage candidates across 46+ therapeutic areas), a strong Japan-anchored consumer health brand portfolio, and an aggressive M&A strategy that has added Transcend Therapeutics (PTSD neuroplastogen, $1.225B 2026), Jnana Therapeutics (PKU, 2024), Cantargia's CAN10 program (~$33M 2025), and prior deals for Visterra and Mindset. Recent strategic activity centers on novel-mechanism assets — APRIL inhibitors (sibeprenlimab), neuroplastogens (methylone), NDSRIs (centanafadine), molecular glues (PDE3A-SLFN12), and SLC transporter modulators (repinatrabit) — alongside digital health partnerships (Vivoo AI nutrition tracking, CART BP pro cuffless blood pressure monitor) and AI-assisted drug discovery collaborations with Schrödinger and xFOREST Therapeutics.

Name

Otsuka Pharmaceutical

Legal name

Otsuka Pharmaceutical Co., Ltd.

Website

https://otsuka.co.jp

Company type

Public

Founded year

1964

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Otsuka Pharmaceutical is a Tokyo-based dual-business healthcare company operating a prescription pharmaceutical business (CNS, oncology, cardiovascular/renal, rare diseases) and a Japan-anchored nutraceuticals/consumer health business (Pocari Sweat, Calorie Mate, Nature Made, SOYJOY, InnerSignal), serving patients via medical representatives and consumers via mass retail and e-commerce globally.

Ownership category

akta.pro rank

Product category

Pharmaceuticals and Consumer Healthcare

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

OTC Medicines & Consumer Health Products Distribution (CRAOAHAB), Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK), Cold, Flu & Cough Remedies (HLAIADAB)

Keywords

• Prescription pharmaceuticals
• Consumer health products
• CNS therapeutics
• Functional beverages
• Renal denervation devices

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical (Prescription Drug) Sales: Revenue from selling prescription pharmaceutical products (originator drugs) through hospital and retail pharmacy channels, primarily in Japan, the US, and Europe. Therapeutic areas include CNS (ABILIFY, Rexulti), oncology, cardiovascular/renal (VOYXACT, NEXLETOL), and others. Otsuka America Inc. handles US commercial operations; Otsuka Pharmaceutical Europe handles EU markets.
2. Nutraceuticals and Consumer Health Products: Revenue from consumer health products including beverages (POCARI SWEAT, OS-1), functional foods (Calorie Mate, SOYJOY), dietary supplements (Nature Made, FIBREMIN, Amino Value), and cosmeceuticals (InnerSignal, UL-OS). Sold through mass retailers, convenience stores, drugstores, and e-commerce in Japan and select international markets.
3. Licensing and Milestone Payments: Revenue from out-licensing pipeline assets and receiving milestone payments from commercial partners. Examples: Esperion received $90M payment when Otsuka launched NEXLETOL in Japan; Biodexa licensed OPB-171775 with upfront fee, milestones, and mid-single digit royalties; 4DMT received $140M upfront for 4D-150 Asia-Pacific license.
4. Pharmavite (Otsuka Subsidiary) - Consumer Supplements: Otsuka's subsidiary Pharmavite (under Otsuka Pharmaceutical) generates revenue from consumer health supplement brands including Nature Made, and Bonafide Health products (Revaree, Ristela) for menopause symptom relief, distributed through mainstream retail (Target) and direct-to-consumer channels.
5. Partnership Revenue and Co-development Royalties: Otsuka receives partnership revenue from co-development arrangements, co-promotion agreements, and royalties. For example: partnership with 4DMT for 4D-150 in Asia-Pacific (Otsuka handles development, regulatory, and commercial activities); GENESIS Pharma partnership for donidalorsen distribution in Central and Eastern Europe.

Pricing tiers

Go-to-market motion4 records

Distribution channels9 records

Marketing channels8 records

Core offering

Otsuka Pharmaceutical operates two core businesses: (1) a pharmaceutical business developing, manufacturing, and commercializing prescription drugs and biologics across CNS, oncology, cardiovascular/renal, rare diseases, and infectious disease (tuberculosis), distributed via medical representative field sales to hospitals, clinics, and physicians; and (2) a nutraceuticals/consumer health business developing and marketing functional beverages, nutritional supplements, women's health products, and cosmedics distributed through mass retail, drugstores, convenience stores, and e-commerce in Japan and select international markets.

Product overview

Otsuka Pharmaceutical operates two core businesses: a pharmaceutical business covering CNS/psychiatry, oncology, cardiovascular/renal, tuberculosis, and ophthalmology, and a nutraceuticals business covering rehydration, nutrition, women's health, soy-based products, and cosmedics. Key pharmaceutical products include VOYXACT (sibeprenlimab-szsi) for IgA nephropathy, Inaqovi (decitabine/cedazuridine) for AML, centanafadine for ADHD, and TSND-201 for PTSD (via Transcend Therapeutics acquisition). The nutraceutical portfolio centers on the Japanese consumer market with flagship brands including Pocari Sweat, Calorie Mate, Nature Made, SOYJOY, and /zeroz, alongside health-focused digital tools like Vivoo (AI urine nutrition tracking). Cosmedics brands include InnerSignal skincare, and Otsuka distributes medical devices such as CART BP pro (cuffless blood pressure ring) and the Paradise Ultrasound Renal Denervation System. The company is headquartered in Tokyo and pursues global expansion through strategic acquisitions (Transcend Therapeutics, Jnana Therapeutics, Cantargia's CAN10 program) and partnerships.

Differentiator

Problem solved

Functional benefit

Brands

• VOYXACT: FDA-approved treatment for primary immunoglobulin A nephropathy (IgAN) that reduces proteinuria
• Inaqovi
• Pocari Sweat
• Calorie Mate
• Nature Made
• Bonafide Health
• Vivoo
• OS-1
• Centanafadine
• Sibeprenlimab (repimatrabit/JNT-517)

Products and services

• VOYXACT (sibeprenlimab-szsi) A targeted APRIL-inhibitor monoclonal antibody biologic for adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression; preserves kidney function (interim +5.5 mL/min/1.73m² eGFR treatment effect vs placebo at 12 months). Sold to hospitals, nephrologists, and specialty renal prescribers under FDA accelerated approval and Japan NHI coverage.
• Inaqovi (decitabine and cedazuridine) An oral fixed-dose hypomethylating agent combination (decitabine + cedazuridine) approved in the EU for adults with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive chemotherapy, used in combination with venetoclax. Distributed to hematologists/oncologists and hospital pharmacies across Europe.
• Centanafadine Investigational first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) for ADHD in children, adolescents, and adults, with Phase 3 data showing improvements in executive function and emotional dysregulation vs placebo. NDA filed with FDA under Priority Review.

Quantifiable outcome

• VOYXACT (sibeprenlimab): +5.5 mL/min/1.73m² eGFR treatment effect vs placebo at 12 months in IgA nephropathy; 82.5% achieved negative microscopic hematuria at 48 weeks vs 52.6% placebo
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature9 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Transcend Therapeutics Inc.coreStrategic or Co-development Partner · 27 March 2026Otsuka Pharmaceutical agreed to acquire Transcend Therapeutics for up to $1.225 billion ($700 million upfront plus up to $525 million in contingent milestones tied to sales), making Transcend a wholly owned subsidiary of Otsuka America Inc. Transcend's lead asset TSND-201 (methylone), a rapid-acting neuroplastogen for PTSD, received FDA Breakthrough Therapy Designation in July 2025. Phase 3 enrollment is ongoing in the US. The deal closed in June 2026. Otsuka has been operating in mental health/CNS since the 1970s and the acquisition adds a differentiated mechanism to its portfolio.
• Jnana Therapeutics Inc.coreTechnology or Integration · 27 March 2026Otsuka acquired Jnana Therapeutics in August/September 2024, gaining access to JNT-517 (repinatrabit), an oral therapy candidate for phenylketonuria, and additional autoimmune pipeline programs. Jnana's platform targets solute carrier (SLC) transporters for small molecule drug discovery. Phase 2 data showed 67% mean reduction in blood phenylalanine in adolescents; pivotal Phase 3 trial ongoing with primary endpoint expected late 2026.
• Sky Labs Inc.coreChannel Partner/ Reseller/ Distributor · 5 February 2026Exclusive distribution agreement for CART BP pro, a cuffless ring-type blood pressure monitor using photoplethysmography (PPG) technology, in Japanese hospital and clinic markets. CART BP pro has been prescribed in over 1,700 medical institutions in Korea with more than 150,000 prescriptions. Otsuka leverages its cardiovascular expertise and distribution network to address Japan's approximately 43 million hypertension patients.
• GENESIS PharmacoreChannel Partner/ Reseller/ Distributor · 15 December 2025Partnership for commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe, covering 14 markets. GENESIS Pharma leverages its regional distribution and regulatory expertise across the CEE region. The European Commission review of donidalorsen's authorization was ongoing as of the partnership announcement.
• 4D Molecular Therapeutics (4DMT)coreStrategic or Co-development Partner · 3 November 2025Exclusive license agreement for 4D-150 (voretigene ruvolc-plasmid, gene therapy for wet age-related macular degeneration and DME) in Asia-Pacific including Japan, South Korea, Taiwan, Australia, and New Zealand. 4DMT received $140 million upfront with potential milestone payments and royalties. Otsuka handles development, regulatory submissions, and commercialization activities in the APAC region.
• Jolly Good Inc.minorStrategic or Co-development PartnerCollaboration to develop Frailty Prevention Support VR training content as part of the FACEDUO program. The VR content enables users to experience early signs of frailty through virtual reality simulations, focusing on three pillars: nutrition, physical activity, and social participation. Under supervision of Professor Katsuya Iijima from the University of Tokyo.
• Bonafide Health (Pharmavite)coreChannel Partner/ Reseller/ DistributorOtsuka's subsidiary Pharmavite owns Bonafide Health, which products Revaree (#1 gynecologist-recommended OTC hyaluronic acid insert for vaginal dryness) and Ristela. Bonafide is expanding from direct-to-consumer into mainstream retail chains like Target. A national survey of 600 gynecologists named Bonafide products top-recommended in their categories for menopause symptom relief.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Takeda Pharmaceutical: Japan's largest pharmaceutical company with a global specialty pharma footprint across CNS, oncology, rare diseases, and gastroenterology. Most directly comparable to Otsuka by domestic market leadership, dual Rx/OTC presence in Japan, and globally diversified revenue base.
• Daiichi Sankyo: Major Japanese specialty pharmaceutical company with strong oncology and cardiovascular franchises, plus OTC/consumer health businesses (Daiichi Sankyo Healthcare). Comparable dual business model, Japanese NHI dependence, and global commercial infrastructure.
• Astellas Pharma: Japanese specialty pharmaceutical company with focus on oncology, women's health, and rare diseases. Comparable scale, Japan-centric historical revenue mix that has shifted global through M&A, and overlap in CNS/urology/cardiovascular therapeutic areas.
• Eisai: Japanese pharmaceutical company with deep CNS franchise (Lecanemab/Aricept legacy) and global neurology focus. Highly comparable therapeutic-area overlap with Otsuka's CNS emphasis and similar Japan-rooted internationalization strategy.
• Shionogi: Japanese specialty pharmaceutical company focused on CNS, infectious disease, and pain. Comparable mid-cap scale, similar global expansion pattern, and overlapping CNS pipeline positioning versus Otsuka's centanafadine and TSND-201.
• Kobayashi Pharmaceutical: Japanese OTC and consumer healthcare company specializing in pharmaceuticals, toiletries, and household products. Direct peer for Otsuka's Japan OTC/nutraceutical segment with overlapping drugstore channel competition and similar domestic market exposure.
• H. Lundbeck: Danish specialty pharmaceutical company with deep CNS franchise and Otsuka's co-promotion partner on Rexulti (brexpiprazole). Highly comparable therapeutic-area focus in psychiatry and neurology with similar specialty/mid-cap global positioning.

Broad incumbents

• Taisho Pharmaceutical: Japan-headquartered OTC and consumer healthcare company (Lipovitan, RiUP) under Taisho Pharmaceutical Holdings. Directly comparable consumer health/OTC portfolio and Japan retail distribution strength that mirrors Otsuka's nutraceutical business.
• Meiji Holdings: Japanese consumer health and nutrition company through Meiji Seika Pharma. Comparable nutraceuticals/supplement portfolio and Japan-centric distribution, though pharma weighting is lower than Otsuka's.

Regional players

• Santen Pharmaceutical: Japanese specialty pharmaceutical company focused on ophthalmology. Comparable Japan-headquartered specialty pharma profile and similar size band; relevant as a regional peer for Otsuka's Japanese specialty franchise though therapeutic-area overlap is partial.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCWATXldJMUJm0gvtZjh18oA
• Facebookfacebook.com/share.php?u=https://www.otsuka.co.jp
• Xx.com/otsukaus

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Otsuka Pharmaceutical